JP2009509974A - 抗癌治療 - Google Patents

抗癌治療 Download PDF

Info

Publication number
JP2009509974A
JP2009509974A JP2008532494A JP2008532494A JP2009509974A JP 2009509974 A JP2009509974 A JP 2009509974A JP 2008532494 A JP2008532494 A JP 2008532494A JP 2008532494 A JP2008532494 A JP 2008532494A JP 2009509974 A JP2009509974 A JP 2009509974A
Authority
JP
Japan
Prior art keywords
glufosfamide
cancer
gemcitabine
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008532494A
Other languages
English (en)
Japanese (ja)
Inventor
ジョージ ティドマーシュ，
ドナルド ティー． ユング，
アラン コロウィック，
Original Assignee
スレッシュオールド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッシュオールド ファーマシューティカルズ， インコーポレイテッド filed Critical スレッシュオールド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2009509974A publication Critical patent/JP2009509974A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008532494A 2005-09-23 2006-09-25 抗癌治療 Withdrawn JP2009509974A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71978705P 2005-09-23 2005-09-23
US76059906P 2006-01-20 2006-01-20
PCT/US2006/037431 WO2007035961A2 (fr) 2005-09-23 2006-09-25 Therapies anticancereuses

Publications (1)

Publication Number Publication Date
JP2009509974A true JP2009509974A (ja) 2009-03-12

Family

ID=37889585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532494A Withdrawn JP2009509974A (ja) 2005-09-23 2006-09-25 抗癌治療

Country Status (2)

Country Link
JP (1) JP2009509974A (fr)
WO (1) WO2007035961A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1917885A (zh) 2004-02-06 2007-02-21 施瑞修德制药公司 抗癌疗法
WO2008124691A1 (fr) 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Traitement combiné au glufosfamide
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA949929B (en) * 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.

Also Published As

Publication number Publication date
WO2007035961A2 (fr) 2007-03-29
WO2007035961A3 (fr) 2007-08-23

Similar Documents

Publication Publication Date Title
Pinto et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
WO2021098679A1 (fr) Utilisation d'un inhibiteur de fak dans la préparation d'un médicament pour le traitement de tumeurs présentant une mutation nras
US9205098B2 (en) Anti-cancer therapies
CN106573051A (zh) 治疗淋巴瘤
US20220265592A1 (en) Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
PT1432402E (pt) Composições para administração de combinações de fármacos
KR20130140032A (ko) 암을 치료하는 방법들
JP2009509974A (ja) 抗癌治療
TW201717926A (zh) 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
WO2017114215A1 (fr) Utilisation de sous-unité de calcineurine b humaine recombinante
CA3231639A1 (fr) Therapie a trois agents pour le traitement du cancer
UA97504C2 (uk) Спосіб зниження ризику виникнення або відстрочення виникнення раку у суб'єкта із застосуванням анти-vegf антитіла
Chang TMHRI IRB-0265T BMS Protocol#: CA163-157

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20091201